Oxford, United Kingdom – 7 th July 2025 – OMass Therapeutics (‘OMass’ or ‘the Company’), a biotechnology company identifying medicines against highly validated target ecosystems such as membrane ...

UK biotech OMass Therapeutics has revealed its first major pharma partnership, with Roche's Genentech unit paying $20 million upfront to tap into its expertise and find small-molecule therapies for ...

OMass Therapeutics (OMass), a biotechnology company identifying medicines against highly validated target ecosystems such as membrane proteins or intracellular complexes, announces that it has entered ...

OMass and Genentech collaborate on a preclinical oral small molecule program for IBD, with OMass receiving $20 million upfront and potential milestone payments up to $400 million. OMass leads initial ...

GV, Northpond Ventures and Sanofi Ventures have joined forces to pump $100 million into OMass Therapeutics, teeing the British biotech up to advance candidates against hard-to-hit targets toward the ...

Oxford, United Kingdom – 26th September 2023 – OMass Therapeutics (‘OMass’ or ‘the Company’), a biotechnology company identifying medicines against highly validated target ecosystems such as membrane ...

Oxford, United Kingdom – 11 October 2023 – OMass Therapeutics (‘OMass’ or ‘the Company’), a biotechnology company identifying medicines against highly validated target ecosystems, is pleased to ...

Oxford, United Kingdom – 28 February 2022 – OMass Therapeutics (‘OMass’ or ‘the Company’), a biotechnology company identifying medicines against highly validated target ecosystems, is pleased to ...

OMass is an Oxford University spin-out backed by Syncona Ltd and Oxford Sciences Innovation that is harnessing high-resolution native mass spectrometry and other biophysical technologies to drive drug ...

Collaboration leverages OMass’ Odyssion TM platform for the continued development of oral small molecules against a first-in-class target in inflammatory bowel disease OMass to receive $20 million ...